Bioadaptor RCT 2 years: could we further improve long-term CAD outcomes vs DES?

Follow this exchange between Antonio Colombo, Stefan Verheye, and Davide Capodanno as they discuss the past, present, and future of drug-eluting stents. They address the current limitations, emphasizing the issue of vessel caging, and suggest improvements, particularly highlighting the new Bioadaptor with uncaging bioresorbable elements that adjusts to vessel movements and physiological behavior. They also present the latest 2-year results from the Bioadaptor randomized clinical trial, showing a 65% reduction in TLF rates, and describe the ideal patient for this promising new technology.

This interview was filmed at EuroPCR 2024: see more videos here.